Levetiracetam: what does this study show?
Nine patients completed a randomized crossover study comparing levetiracetam 1,500 mg with brivaracetam 100 mg as 5- or 15-minute intravenous infusions.
Both suppressed the light-triggered EEG response. Combined analysis favored faster suppression with brivaracetam; separate infusion-duration comparisons were not statistically significant.
A small laboratory EEG endpoint study, not a long-term seizure-outcome or cognition trial. No serious or severe adverse effects occurred.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
A small laboratory EEG endpoint study, not a long-term seizure-outcome or cognition trial. No serious or severe adverse effects occurred.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.